Introduction
============

Gastric cancer is an important health problem, being the fifth most common cancer and the third leading cause of cancer-related death worldwide [@B1]. More than 950,000 new diagnoses are made every year [@B2]. In China, although the incidence has decreased over past several decades, gastric cancer still ranks the second most common malignancy with an estimated 679,100 new cases each year[@B3]. Due to the lack of specific symptoms at the early stage, over 80% of patients with gastric cancer are diagnosed at an advanced and unsuitable stage for surgical resection, which is the major reason for a poor prognosis [@B3]. Tumor-node-metastasis (TNM) staging system has been widely used to provide reliable prognostic information of gastric cancer, but they still have limited capacity to determine different outcomes for ignoring the heterogeneity of gastric cancer. Considering the increasing level of understanding of the molecular basis of tumor biology, more novel biomarkers are applied in diagnosis, prognosis and treatment [@B4].

Tetranectin, a homotrimeric C-type lectin originally isolated from plasma, was detected to bind with plasminogen and fibrin [@B5]. It is thought to play an important role in the regulation of proteolytic processes via binding to plasminogen [@B5]. Impaired cutaneous wound healing, delayed fracture healing and features of Parkinson disease were found in mice lacking tetranectin [@B6]-[@B8]. In malignancies, preoperative serum tetranectin was supposed to be a significant prognostic marker in advanced ovarian cancer patients [@B9]. The alteration of tetranectin expression in cancer tissue is also considered as a potential biomarker predicting prognosis in breast [@B10], bladder [@B11], oral [@B12] and ovarian cancer [@B13]. Nevertheless, the roles of tetranectin in gastric carcinoma remain poorly understood.

The aim of the present study was to investigate the expression of tetranectin in gastric cancer specimens and explore its associations with clinicopathological factors and prognosis. We also evaluated whether integration of intratumoral tetranectin expression could generate a predictive nomogram to refine the risk stratification system for prognosis of patients with gastric cancer.

Materials and Methods
=====================

Patient samples
---------------

A total of 328 consecutive gastric cancer patients who received standard gastrectomy with D2 dissection from the same surgical team in Zhongshan Hospital of Fudan University (Shanghai, China) between May 2002 and April 2006 were enrolled in the study. We retrospectively collected the baseline demographic and clinicopathological factors of these patients, including age, gender, tumor location, tumor differentiation, Lauren classification, and tumor stage. Tumor stage and tumor differentiation were reassessed by two independent gastroenterology pathologists according to the 2010 International Union Against Cancer TNM classification system. All patients were followed up until July 2012, with a median follow-up time of 59 months. OS was defined as the time between the dates of surgery and death or last visit. No patients received any preoperative anticancer treatment. All methods were approved by the research medical ethics committee of Fudan University and were carried out in accordance with the approved guidelines. Informed consent on the use of clinical specimens were obtained from all patients.

TCGA and GEO datasets
---------------------

These data are publically available from the Cancer Genome Atlas and the NCBI Gene Expression Omnibus (accession number: GSE27342 and GSE13911). For the TCGA dataset, all level-3 data were downloaded from the TCGA-STAD portal by using TCGA-Assembler software[@B14]. The mRNA expression in TCGA dataset was measured by RNA sequencing V2. The RSEM (RNA-Seq by Expectation-Maximization) counts were further normalized by TMM (trimmed mean of M value) method to estimate the relative RNA production levels using edgeR software[@B15]. For the Gene Expression Omnibus dataset reported previously, the mRNA expression was measured by microarray. The probe set intensities were quantified using the GeneChip Operating Software (GCOS) and normalized with GCRMA (GeneChip Robust Multiarray Averaging) using Array Assist Software.

IHC staining and evaluation
---------------------------

Tissue microarray on glass slides was deparaffinized in xylene, dehydrated in graded ethanol and subjected to antigen retrieval in boiling citrate buffer (0.01 M, pH 6.0). Then, the sections were blocked by UltraVision Hydrogen Peroxide Block (Thermo Scientific, CA, USA) and UltraVision Protein Block (Thermo Scientific), followed by primary antibody incubation (1:1000; Abcam, USA). UltraVision Quanto Detection System horseradish peroxidase (HRP) Polymer (Thermo Scientific) and DAB Quanto (Thermo Scientific) were applied staining and hematoxylin was used for counterstaining. We also make an H.E staining of the tissue microarray to discriminate tumor part and other part. The staining in gastric cancer cells, not the stromal part of the cancer tissue, were calculated. The staining intensity was categorized as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. Depending on the staining extent, the area was categorized as follows: 0, \<5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, \>75%. The staining score was calculated by combining staining intensity and area, yielding a series of results ranging from 0 to 12 according to our previous report [@B16]. The best cut off point was determined by the ROC analysis.

Statistical analysis
--------------------

Analyses were performed with SPSS 19.0 (SPSS Inc., Chicago, IL) and R software version 3.0.2 and the "rms" package (R Foundation for Statistical Computing, Vienna, Austria). Chi-square test was used to compare categorical variables. Cox proportional hazards model was used to perform univariate and multivariate analysis. Kaplan-Meier analysis was used to determine the survival and log-rank test was used to compare the patient survival between subgroups. The area under the receiver operating characteristic curves (AUC) at different cut-off values of OS time was calculated to determine the optimal cut-off value of the tetranectin expression in tumors. Nomogram was created by R software using "rms" package. Calibration plots were generated to examine the performance characteristics of the predictive nomogram. The Harrell\'s concordance index (C-Index) and Akaike information criterion (AIC) were used to measure the prognostic accuracy. All statistical analyses were two-sided and *P* \< 0.05 was regarded as statistically significant.

Results
=======

The expression of tetranectin in gastric cancer
-----------------------------------------------

We first screened differentially expressed members of C-type lectin family in the TCGA-STAD dataset. Results demonstrated that among the various members of CLEC family, the mRNA expression of *clec3b* in gastric cancer tissues displays the most significant fold-change by comparing with that in normal gastric mucosa (Table [1](#T1){ref-type="table"}).Statistical analysis also indicated that the tetranectin expression was remarkably down-regulated in gastric cancer tissues in TCGA (P \< 0.001), GSE27342 (P \< 0.001) and GSE13911 (P \< 0.001) datasets (Fig. [1](#F1){ref-type="fig"}a-c).

Next we investigated the expression of tetranectin in 328 cases of gastric cancer with tissue microarray. The representative staining of tetranectin in tumor tissues and adjacent normal tissues were shown in Figure [1](#F1){ref-type="fig"}d. In comparison to the H.E staining, it revealed that the expression of tetranectin was mostly in the cytoplasm of gastric epithelial cells, not the stromal part of the cancer tissue (Figure [S1](#SM0){ref-type="supplementary-material"}). Statistical analysis confirmed that tetranectin staining score in tumor tissue was significantly lower than that in normal gastric epithelium (P \< 0.001) (Fig. [1](#F1){ref-type="fig"}e). These results suggest that the expression of tetranectin is down-regulated in gastric cancer.

Correlation between tetranectin expression and clinicopathological features in gastric cancer
---------------------------------------------------------------------------------------------

According to the results conducted by receiver operating characteristic (ROC) curve analysis, IHC score of 6 was determined as the cut-off to dichotomize the patients into tetranectin low expression group (score, 0-6; n = 221) and tetranectin high expression group (score, 7-12; n = 107). The correlations between tetranectin expression and clinicopathological features in 328 gastric cancer samples were also explored with the chi-square test (Table [2](#T2){ref-type="table"}). Among the variables, higher expression of tetranectin was positively associated with tumor invasion (P = 0.013), lymph node metastasis (P = 0.005), advanced TNM stage (P = 0.003) and younger age (P = 0.024). No other clinicopathological variables showed a significant difference between tetranectin high and low expression group. We also assessed the expression of tetranectin among different tissue components in the same patient. It showed an increasing expression of tetranectin in invasive part than the normal and in situ part (Figure [S2](#SM0){ref-type="supplementary-material"}).

Prognostic value of tetranectin expression in gastric cancer
------------------------------------------------------------

We next explored the relationship between tetranectin expression and overall survival (OS) in patients with gastric cancer after gastrectomy using Kaplan-Meier analysis. The results demonstrated that high tetranectin expression was associated with poor OS (P \< 0.001) (Fig. [2](#F2){ref-type="fig"}a). To further evaluate the efficiency of tetranectin expression in stratifying patients with different TNM stages, we divided the patients into early (I-II) and advanced (III- IV) groups. In both TNM I-II and TNM III-IV groups, tetranectin expression showed statistically significant value in predicting the outcomes of gastric cancer patients (Fig. [2](#F2){ref-type="fig"}b, c). These data suggest that tetranectin expression is correlated with OS for patients with gastric cancer.

Tetranectin expression is identified as an independent prognosticator in patients with gastric cancer
-----------------------------------------------------------------------------------------------------

Univariate Cox regression analysis was conducted to identify the prognostic significance of clinicopathological factors for OS. Lauren classification (P \< 0.001), T classification (P \< 0.001), N classification (P \< 0.001), distant metastasis (P = 0.004), TNM stage (P \< 0.001) and tetranectin expression (P \< 0.001) were defined as risk factors that may affect the OS of gastric cancer patients (Table [3](#T3){ref-type="table"}). After adjustment of covariate factors by using multivariate Cox analysis, we identified Lauren classification (P \< 0.001), T classification (P = 0.006), N classification (P = 0.001), distant metastasis (P = 0.001), and tetranectin expression (P \< 0.001) as independent prognostic factors for OS (Table [3](#T3){ref-type="table"}).

Combination of tetranectin expression with TNM stage generates a better predictive model for overall survival of gastric cancer patients
----------------------------------------------------------------------------------------------------------------------------------------

To improve the prognostic accuracy for OS of patients with gastric cancer after gastrectomy, we combined tetranectin expression and TNM staging system together to generate a predictive model. ROC curve analysis showed that the combination of tetranectin and TNM stage revealed better prognostic value (AUC \[95% CI\], 0.749 \[0.686-0.813\]) than tetranectin expression alone (AUC \[95% CI\], 0.657 \[0.592-0.721\]) or TNM stage alone (AUC \[95% CI\], 0.672 \[0.598-0.747\]) with statistical significance (Fig. [3](#F3){ref-type="fig"}a). In addition, the AIC was 2647.21 when estimated according to TNM stage alone, and it decreased to 2595.652 when estimated in combination with tetranectin expression. The C-index was 0.635 when estimated according to TNM stage alone, and it increased to 0.700 when tetranectin expression was added (Table [4](#T4){ref-type="table"}).

We also conducted a predictive nomogram by combing all independent prognostic factors after multivariate Cox regression analysis (Fig. [3](#F3){ref-type="fig"}b). In the nomogram, a higher total point predicts a worse prognosis. The total point was calculated by adding the score of Lauren classification, T stage, N stage, M stage and tetranectin expression respectively. The calibration curve for predicted 5-year OS performed well with the ideal mode (Fig. [3](#F3){ref-type="fig"}c). We next stratified the 328 patients with gastric cancer into 3 groups according to the points calculated by the nomogram: low-risk (\< 25th percentile), intermediate-risk (25th-75th percentile), and high-risk (\> 75th percentile) groups (Fig. [3](#F3){ref-type="fig"}d). The results showed that the nomogram could effectively discriminate the risk of OS in patients with gastric cancer.

Discussion
==========

It is well recognized that gastric cancer is a highly heterogeneous disease with poor clinical outcome. To provide a predictive model for patients with gastric cancer, traditional TNM staging system and the Lauren classification were commonly used in clinical practice [@B17], [@B18]. Nevertheless, these predictive models still have a limit in their ability to discriminate a subset of patients when referring to the molecular heterogeneity of gastric cancer [@B19]. Classification of gastric carcinomas based on molecular subtypes are supposed to be used in the near future to determine prognosis and to customise treatment [@B1]. Recently, the Asian Cancer Research Group (ACRG) applied gene expression profiling and defined four distinct gastric cancer molecular subtypes that are associated with distinct genomic alterations, survival outcome and recurrence patterns after surgery [@B20], which shows prognostic value of gastric cancer by using molecular approaches. Moreover, molecular classification based on human epidermal growth factor receptor 2 (HER2; also known as ERBB2) status has been introduced in gastric cancers because of therapeutic implications [@B21]. In our study, we found a significant association between high tetranectin expression and poor prognosis in gastric cancer patients following surgery, and the molecular mechanism and potential functions of tetranectin in gastric cancer needs further investigation.

Tetranectin belongs to the family of C-type lectins that bind specifically to kringle four of plasminogen [@B22]. C-type lectins are a kind of carbohydrate-binding molecules whose functions span many areas of immunity and homeostasis [@B23]. Recent studies have suggested the potential correlation between C-type lectins and carcinogenesis including gastric cancer [@B24]. Our recent research also indicated that C-type lectin receptor CLEC-2 suppressed AKT signaling and invasive activities of gastric cancer cells by blocking expression of PI3K subunits [@B25]. The expression pattern of tetranectin has also been described in several types of human carcinomas. Serum tetranectin have shown great distinguishing ability between autoimmune pancreatitis and pancreatic cancer [@B26], as well as benign ovarian lesions and malignant ovarian tumors [@B27]. However, the role of intratumoral tetranectin expression as a tumor prognostic factor remains controversial. High tetranectin expression were found to be associated with poor survival in breast cancer [@B10] and bladder cancer [@B11], while positive expression of tetranectin predicted a favorable survival prognosis in women diagnosed with ovarian cancer [@B13].

The mechanisms of tetranectin in human malignancies are being explored. It has been reported that tetranectin plays an important role in regulating the fibrinolysis and proteolytic procedures by binding to kringle four of circulating plasminogen to enhance activation of plasminogen into plasmin [@B28]. Although the precise biological function of tetranectin has not yet been clarified, it shows co-localization with plasminogen at the invasion front of melanomas, suggesting a role in cancer invasion and metastases [@B29]. Increased diffuse cytoplasmic immunoreactivity of urokinase-type plasminogen activator (u-PA) were also found in neoplastic columnar epithelial cells of colon carcinoma while intense immunoreactivity for tetranectin in the stroma surrounding the tumor cells simultaneously [@B30]. As u-PA is found up-regulated in gastric cancer cells to enhance invasiveness [@B31], [@B32], tetranectin were hypothesized to combine with, or get close proximity to u-PA to enhance tumor associated proteolytic activity [@B30]. Since proteolytic activity is essential for tumor growth, invasion, and metastasis [@B33], it is in accordance with our observations that high expression of tetranectin was associated with increased invasiveness and metastasis in gastric cancer. These data imply that tetranectin may play an important role in proteolytic activity to enhance invasion and metastasis of gastric cancer, while the exact mechanisms still needs further investigation.

Although the clinical significance of tetranectin in gastric cancer has been presented in our study, some limitations of this study should be acknowledged. First, the number of patients enrolled in this study was relatively small. Second, our data lack the serum levels of tetranectin. Third, single cohort seems to be inadequate to reach greater reliability. Thus, a large, multi-center, prospective data is needed to validate these results and more efforts need to be exerted in the future studies.

In summary, our data indicated that high intratumoral expression of tetranectin correlated with tumor invasion and metastasis of gastric cancer, and was identified as an independent inferior prognostic factor of OS for patients after gastrectomy. Incorporation of tetranectin expression with TNM staging system or other predictive models might add some prognostic information for patients\' survival.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures.

###### 

Click here for additional data file.

This study was funded by grants from National Natural Science Foundation of China (81672925, 31670806, 81572317, 31370808, 81302259, 31500645, 31630088). All these study sponsors have no roles in the study design, in the collection, analysis, and interpretation of data.
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![ROC curve and nomogram for predicting prognosis in patients with gastric cancer. (a) ROC curve analysis of the sensitivity and specificity for the predictive value of the TNM model, the tetranectin model, and the combined TNM and tetranectin stratification model. (b) Predictive nomogram for 3-year and 5-year overall survival was generated by combining proven independent prognostic factors including Lauren classification, T stage, N stage, M stage and tetranectin expression. (c) Calibration plot for nomogram predicting observed 5-year survival rate. Gray Line: ideal model; vertical bars, 95% confident interval. (d) Kaplan-Meier curves of overall survival based on risk score calculated by nomogram. *P*-value was assessed by log-rank test.](jcav08p3623g003){#F3}

###### 

Differentially expressed members of CLEC family in TCGA dataset.

  Gene           Log FC   P-value
  -------------- -------- ---------
  *clec1a*       -0.421   0.006
  *clec2b*       -0.603   0.000
  *clec2d*       0.344    0.015
  *clec2l*       0.238    0.710
  *clec3a*       -2.617   0.000
  ***clec3b***   -3.490   0.000
  *clec4a*       0.482    0.027
  *clec4d*       0.482    0.202
  *clec4e*       0.584    0.083
  *clec4f*       -1.209   0.000
  *clec4g*       -2.273   0.000
  *clec5a*       2.345    0.000
  *clec7a*       0.574    0.015
  *clec9a*       -1.324   0.000
  *clec10a*      -2.075   0.000
  *clec11a*      0.334    0.214
  *clec12a*      0.477    0.113
  *clec14a*      -0.403   0.007
  *clec16a*      0.103    0.255
  *clec17a*      -0.118   0.902
  *clec18a*      0.544    0.060
  *clec18b*      0.279    0.427
  *clecl1*       -0.407   0.318

Abbreviations: FC, fold change.

###### 

Correlation between tetranectin expression and clinicopathological characteristics in patients with gastric cancer.

  Clinicopathological Characteristics   No.   Tetranectinlow   \%   Tetranectinhigh   \%   *P* -value
  ------------------------------------- ----- ---------------- ---- ----------------- ---- ------------
                                        328                                                
  Gender                                                                                   0.596
  Male                                  215   147              68   68                32   
  Female                                113   74               65   39                35   
  Age                                                                                      **0.024**
  \< 60                                 158   116              73   42                27   
  ≧60                                   170   105              62   65                38   
  Tumor location                                                                           0.739
  Cardiac                               40    25               63   15                38   
  Body                                  82    57               70   25                30   
  Pylorus                               206   139              67   67                33   
  Tumor differentiation                                                                    0.703
  Well                                  13    10               77   3                 23   
  Moderate                              51    33               65   18                35   
  Poor                                  264   178              67   86                33   
  Lauren classification                                                                    0.266
  Diffused Type                         137   95               69   42                31   
  Intestinal Type                       180   121              67   59                33   
  Mixed Type                            11    5                45   6                 55   
  T                                                                                        **0.013**
  T1                                    71    58               82   13                18   
  T2                                    30    21               70   9                 30   
  T3                                    84    57               68   27                32   
  T4                                    143   85               59   58                41   
  N                                                                                        **0.005**
  N0                                    103   77               75   26                25   
  N1                                    55    41               75   14                25   
  N2                                    64    44               69   20                31   
  N3                                    106   59               56   47                44   
  M                                                                                        0.137
  M0                                    318   217              68   102               32   
  M1                                    10    4                40   5                 50   
  TNM stages                                                                               **0.003**
  I                                     73    61               84   12                16   
  II                                    76    52               68   24                32   
  III                                   170   104              61   66                39   
  IV                                    9     4                44   5                 56   

###### 

Univariate and multivariate Cox regression analysis of clinicopathological characteristics influencing the overall survival of gastric cancer patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                  Univariate                               Multivariate                 
  ---------------------------------------------------------- ------------ ------------- ------------- -------------- ------------- -------------
  Gender:\                                                   0.954        0.737-1.236   0.723                                      
  male versus female                                                                                                               

  Age (Year):\                                               1.234        0.966-1.576   0.093                                      
  ≥60 versus \< 60                                                                                                                 

  Tumor Location: cardia + body versus antrum                0.856        0.666-1.1     0.224                                      

  Differentiation:\                                          1.973        0.931-4.182   0.076                                      
  poorly +moderately\                                                                                                              
  versus well                                                                                                                      

  Lauren classification: diffused +mixed versus intestinal   2.007        1.564-2.577   **\<0.001**   1.96           1.516-2.534   **\<0.001**

  T classification:\                                         2.492        1.764-3.521   **\<0.001**   1.754          1.173-2.623   **0.006**
  T2-4 versus T1                                                                                                                   

  N classification:\                                         2.047        1.596-2.624   **\<0.001**   1.779          1.286-2.461   **0.001**
  N2+N3 versus N0+N1                                                                                                               

  M classification:\                                         2.708        1.385-5.292   **0.004**     3.381          1.685-6.783   **0.001**
  M1 versus M0                                                                                                                     

  TNM stage:\                                                2.055        1.599-2.641   **\<0.001**   0.952          0.665-1.362   0.787
  III+IV versus I+II                                                                                                               

  Tetranectin expression:\                                   3.039        2.351-3.927   **\<0.001**   2.848          2.192-3.702   **\<0.001**
  high versus low                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: P \< 0.05 was considered statistically significant.

###### 

AIC and Harrell\'s C-index analysis of the comparison of the predictive accuracies of different models.

  Model              AIC        C-index   95% CI
  ------------------ ---------- --------- -------------
  TNM                2647.21    0.635     0.605-0.666
  Tetranectin        2628.349   0.632     0.604-0.659
  TNM+ Tetranectin   2595.652   0.700     0.671-0.730
  Nomogram           2559.376   0.741     0.715-0.767

Abbreviations: AIC, Akaike information criterion; C-index, Harrell\'s concordance index; CI, confident interval.
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